Basel, 15 December 2004
New
structure of the Roche Corporate Executive Committee
At its recent
meeting, the Board of Directors of Roche Holding decided on the following changes in the Corporate Executive
Committee, effective 1 January, 2005:
William M. Burns, head of Roche’s
pharmaceuticals
business, is appointed CEO Division Roche Pharma. Heino von Prondzynski, head of the Group’s diagnostics
business is appointed CEO Division Roche Diagnostics.
Erich Hunziker,
Chief Financial Officer is appointed Deputy Head of the Corporate Executive Committee (CEC). He will
chair the CEC meetings in the absence of the Roche Group’s Chief Executive Officer, Franz B. Humer.
Richard
Laube, head of Roche’s OTC business which was recently acquired by Bayer will step down from the CEC
at the end of the year.
The following managers are appointed as permanent
participants of the Corporate Executive Committee: Eduard Holdener, Head Global Pharma Development;
Peter Hug, Head Pharma Partnering; Staffan Ek, Head Diabetes Care; Rolf Schläpfer, Head Corporate Communications.
Per 1 January, 2005, the Corporate Executive Committee of Roche will be composed as
follows:
Corporate Executive Committee:
| Chairman
and CEO
of the Roche Group | Franz B. Humer (1946) |
| CEO Division Roche Pharma | William M. Burns (1947) |
| CEO Division Roche Diagnostics | Heino von Prondzynski (1949) |
| Chief Financial Officer | Erich
Hunziker (1953) |
| Head Global Research | Jonathan
K. C. Knowles (1947) |
| Head Corporate Services and Human Resources | Gottlieb
A. Keller (1954) |
| | |
| Permanent
Participants: | |
| Head Global Pharma Development | Eduard E. Holdener (1945) |
| Head
Pharma Partnering | Peter Hug (1958) |
| Head of
Roche Diagnostics’ business area Diabetes Care | Staffan Ek (1945) |
| Head
Corporate Communications | Rolf D. Schläpfer (1956) |
| President
and CEO, Chugai | Osamu Nagayama (1947) |
| | |
| Secretary: | |
| Head Chairman's Office | Pierre Jaccoud (1955) |
Franz
B. Humer, Chairman and CEO of Roche: „The new structure is the result of the consistent change of Roche
towards a focused healthcare group with two innovative businesses Pharma and Diagnostics spanning the
entire spectrum of healthcare products - from early detection to diagnosis to treatment of diseases.
With these changes our leadership has a broad basis and deputizing is clearly established. Key areas
related to internal and external sources of innovation are now represented at the most senior level
of the organization together with key businesses and corporate functions. The new structure will also
allow me to focus even more on my role as Chairman of the Board of Directors.”
After
his board examination and thesis Swiss medical doctor Eduard Holdener (1945) worked in internal medicine
and as an oncologist at various Swiss hospitals and in clinical research at the University of Kansas,
USA. In 1986, he started in Roche’s oncology team of clinical research and later became the head of
this team. In 1995 he was appointed head of Pharma Development of Roche Japan and in 1999 head of Global
Pharma Development.
Peter Hug (1958) is a Swiss national with a PhD
in economics. He joined Roche in 1983 where he held various marketing positions in Pharma in Switzerland,
Canada and Greece and later was promoted General Manager of Uruguay, Switzerland and Spain. In between
he headed Roche’s diagnostics business in Germany. In September 2004 Peter Hug took over his current
position of Head of Pharma Partnering.
Staffan Ek (1945) a Swedish citizen
with a university degree in business administration started as a marketing consultant before working
over twenty years at Pharmacia. In 1994 he took over the diabetes care business of Boehringer Mannheim,
the German healthcare company which later was acquired by Roche. As Head of the Roche Diabetes Care
he runs the biggest business unit of Roche Diagnostics.
Rolf Schläpfer
(1956) is a Swiss citizen and has a university degree in economics. Following his studies, he held various
management positions in marketing and communications. He was managing director and partner of the consultancy
firm Wirz Identity before joining Roche in 1997 as Head of Roche Corporate Communications department
which includes internal and external communications and public affairs.
Divisional
Management
Pharma Executive Committee:
| William Burns | CEO
Division Roche Pharma |
| George Abercrombie | North America |
| Jennifer
Allerton | Informatics |
| Peter Hug | Pharma Partnering |
| Eduard
Holdener | Development |
| Jonathan Knowles | Research |
| Dominic
Moorhead | Finance and Controlling |
| Paul Newton-Syms | Human
Resources |
| Charles Sabbah | Strategic Marketing |
| Claude
Schreiner | Western Europe |
| Jan van Koeveringe | Technical
Operations |
Diagnostics
Executive Team:
| Heino
von Prondzynski | CEO Division Roche Diagnostics |
| Heiner Dreismann | Molecular
Diagnostics |
| Staffan Ek | Diabetes Care |
| Christian
Hebich | Finance and Services |
| Volker Pfahlert | Applied
Science |
| Burkhard Piper | Centralized Diagnostics |
| Jürgen
Schwiezer | Region EMEA |
| Robert Yates | Business
Development |
About
Roche
Headquartered in Basel, Switzerland,
Roche is one of the world’s leading research-intensive healthcare groups. Its core businesses are pharmaceuticals
and diagnostics. As a supplier of innovative products and services for the prevention, diagnosis and
treatment of disease, the Group contributes on a broad range of fronts to improving people’s health
and quality of life. Roche is a world leader in diagnostics, the leading supplier of medicines for cancer
and transplantation and a market leader in virology. In 2003, the Pharmaceuticals Division generated
19.8 billion Swiss francs in prescription drug sales, while the Diagnostics Division posted sales of
7.4 billion Swiss francs. Roche employs roughly 65,000 people in 150 countries and has R&D agreements
and strategic alliances with numerous partners, including majority ownership interests in Genentech
and Chugai.
|
 |
print this page